Sarepta therapeutics announces fda acceptance of casimersen nda for patients with dmd amenable to skipping exon 45

Sarepta therapeutics announces fda acceptance of casimersen (srp-4045) new drug application for patients with duchenne muscular dystrophy amenable to skipping exon 45.sarepta therapeutics announces fda acceptance of casimersen (srp-4045) new drug application for patients with duchenne muscular dystrophy amenable to skipping exon 45.sarepta therapeutics inc - fda grants priority review status and sets regulatory action date for february 25, 2021.sarepta therapeutics inc - fda has indicated it does not currently plan to hold an advisory committee meeting to discuss application.sarepta therapeutics inc - received fda's conditional approval of amondys 45™ as brand name for casimersen.
SRPT Ratings Summary
SRPT Quant Ranking